Pharma Company Tells High Court Petitioner Not Entitled To Invoke Arthrex
WASHINGTON, D.C. — A generic drug manufacturer that prevailed in both an inter partes review (IPR) of a competitor's patents and a subsequent Federal Circuit U.S. Court of Appeals ruling filed...To view the full article, register now.
Already a subscriber? Click here to view full article